KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference
18 Mars 2024 - 10:24PM
Business Wire
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or
the “Company”), a leading medical technology company focused on
development, manufacturing, and commercialization of innovative and
patient-centric large volume subcutaneous infusion solutions, is
pleased to announce data on the impact of the Freedom Infusion
System on subcutaneous immunoglobulin (SCIg) therapy for primary
immunodeficiency diseases (PIDD) to be presented at the National
Home Infusion Association (NHIA) 2024 Conference. The conference
will take place from March 23 to 27 in Austin, Texas.
The study, authored by KORU Medical, analyzed data from a large
national specialty pharmacy, capturing drug receipts over 4.5 years
for 3,787 US PIDD patients using KORU Medical FREEDOM60® and
FreedomEdge® infusion systems for self-administered SCIg therapy.
Ages ranged from 1 year to 98 years, with a mean of 50.1 years.
Patient drug administration volumes ranged from 5mL to greater than
100mL with the majority of patients administering under 50mL.
Adherence to SCIg therapy using the KORU Medical FREEDOM60® and
FreedomEdge® infusion systems was calculated at 97%.
The abstract, titled "Exploring the Impact of KORU Freedom
Infusion Systems on Subcutaneous Immunoglobulin Therapy for Primary
Immunodeficiency: Insights from a Large-Scale Database Analysis,”
will be presented by Brent Rutland, Vice-President of Medical
Affairs for KORU Medical. This study represents the largest cohort
of PIDD patients in the literature. We believe it provides valuable
insights into the effectiveness of KORU Medical’s Freedom Infusion
System in promoting treatment compliance in large volume
subcutaneous delivery.
“These findings highlight the positive impact of KORU Medical’s
Freedom Infusion System on subcutaneous immunoglobulin therapy for
patients with primary immunodeficiency disease," said Brent
Rutland, Vice President, Medical Affairs at KORU Medical. "The high
adherence rate underscores the effectiveness of KORU Medical’s
pumps in promoting treatment compliance and improving patient
outcomes. These results, with the KORU Freedom Infusion System,
also demonstrate the company’s potential to support a broader range
of developmental subcutaneous drug therapies.”
About KORU Medical Systems
KORU Medical develops, manufactures, and commercializes
innovative and patient-centric large volume subcutaneous infusion
solutions that improve quality of life for patients around the
world. The FREEDOM Syringe Infusion System (the “Freedom System”)
currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion
Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous
Safety Needle Sets™. These devices are used for infusions
administered in the home and alternate care settings. For more
information, please visit www.korumedical.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties. All statements that are not
historical fact are forward-looking statements and can be
identified by words such as “will,” "believe" and "potential".
Actual results may differ materially from these statements due to
potential risks and uncertainties such as, among others, those
risks and uncertainties included under the captions "Risk Factors"
in our Annual Report on Form 10-K for the year ended December 31,
2023, which is on file with the SEC and available on our website at
www.korumedical.com/investors and on the SEC website at
www.sec.gov. All information provided in this release and in the
attachments is as of March 18, 2024. Undue reliance should not be
placed on the forward-looking statements in this press release,
which are based on information available to us on the date hereof.
We undertake no duty to update this information unless required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240318095980/en/
Investor Contact: Louisa Smith
investor@korumedical.com
KORU Medical Systems (NASDAQ:KRMD)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
KORU Medical Systems (NASDAQ:KRMD)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025